sponsored
PatientsVille.com Logo

PatientsVille

Loin Medical Research Studies

Up-to-date List of Loin Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Loin Medical Research Studies

Rank Status Study
1 Not yet recruiting Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy
Condition: Atrial Fibrillation
Interventions: Drug: Vitamin K antagonist;   Drug: Apixaban
Outcome Measures: death and serious cardiovascular events;   any bleeding event;   major bleeding events acc. to the ISTH and TIMI definitions;   strokes, other systemic embolic events and all-cause death;   time from randomisation to ablation;   nights spent in hospital after ablation;   health-care related cost calculation;   hospitalizations for cardiovascular reasons;   Treatment duration prior to ablation and total time on oral anticoagulation;   patients with clinically indicated TEE;   ACT during ablation;   recurrent Atrial Fibrillation (AF);   rhythm status at the end of follow-up;   vascular access complications leading to prolongation of in-hospital stay or specific therapy;   Quality-of-life changes;   cognitive function change;   clinically "silent" MRI-detected brain lesions;   Impact of ablation-associated clinically overt strokes or MRI-detected bus clincally "silent" acute brain lesions on cognitive function after ablation
2 Not yet recruiting Clinical Evaluation of the RAVI-Guide
Condition: Retinal Diseases
Intervention:
Outcome Measures: Pain severity associated with instrument type used for holding eyelids open during intravitreal injection;   Procedural Complications associated with instrument use during intravitreal injection procedure
3 Recruiting Singapore INfra-Genicular Angioplasty With PAclitaxel-eluting Balloon for Critical Limb Ischaemia (SINGA-PACLI) Trial
Condition: Peripheral Arterial Disease
Interventions: Device: CB-PTA;   Device: DEB-PTA
Outcome Measures: Primary patency of the treated (index) site at 6 months;   Limb-salvage rate;   Primary patency of the treated (index) site;   Clinical categorisation of the treated ischemic leg;   Minor amputation;   Infrapopliteal surgical bypass of the trial leg;   Infrapopliteal endovascular re-intervention of the trial leg;   Primary patency of treated femoropopliteal sites;   Peri-procedural complications;   Death;   Incremental cost-effectiveness ratio (ICER)
4 Recruiting Trial Comparing Metal Versus Plastic Stents for Preoperative Biliary Decompression
Conditions: Obstructive Jaundice;   Pancreatic Cancer
Interventions: Procedure: Stent Dysfunction;   Procedure: Complications
Outcome Measures: Complications related to stent dysfunction;   Procedural complications
5 Recruiting Allogeneic Islet Cells Transplanted Into the Omentum
Conditions: Type 1 Diabetes Mellitus;   Hypoglycemia;   Hypoglycemia Unawareness
Intervention: Biological: Islet transplantation
Outcome Measures: A1c </= 6.5% and no severe hypoglycemia;   procedural complications
6 Recruiting PlasmaKinetic (PK) Button Vaporization Electrode for Treatment of Bladder Tumors
Condition: Bladder Cancer
Interventions: Device: Monopolar electrocautery loop in Transurethral resection of bladder tumors;   Device: PK Button Vaporization Electrode in transurethral resection of bladder tumors
Outcome Measures: Procedural complications;   Operative follow-up
7 Recruiting WATCHMAN Asia Pacific Registry
Condition: Atrial Fibrillation
Intervention: Device: WATCHMAN LAA Closure Technology
Outcome Measures: Procedural Complications;   Stroke;   Death
8 Recruiting Registry on WATCHMAN Outcomes in Real-Life Utilization
Condition: Patients With Atrial Fibrillation at Risk for Thrombus Formation, Thromboembolism, Stroke
Intervention:
Outcome Measures: Procedural complications;   Stroke;   Death
9 Recruiting Comparison of Metal and Plastic Stents for Preoperative Biliary Decompression
Conditions: Obstructive Jaundice;   Pancreatic Cancer
Interventions: Procedure: Metal stent placement in the bile duct;   Procedure: Plastic stent
Outcome Measures: Complications related to stent dysfunction;   Procedural complications
10 Unknown  PRISM Cardiac Resynchronisation Therapy (CRT) Randomised Controlled Trial
Condition: Heart Failure
Interventions: Other: Advanced Imaging Guided LV lead placement;   Device: Standard LV lead placement
Outcome Measures: Change in the proportion of CRT responders;   Change in echo derived end systolic (ESV) and diastolic volumes;   Six month assessment of change in 6 minute walk distance and VO2 max (CPEX);   Procedural success;   Procedure duration;   Radiation dose;   Contrast dose;   Procedural complications
11 Recruiting TIPS Combined With Variceal Embolization for the Prevention of Variceal Rebleeding in Patients With Cirrhosis
Condition: Liver Cirrhosis
Interventions: Procedure: TIPS;   Procedure: Embolization
Outcome Measures: variceal rebleeding;   all cause rebleeding;   shunt dysfunction;   hepatic encephalopathy;   Child-Pugh score changing by 2 or more points or MELD score by 4 or more;   mortality;   procedural complications
12 Recruiting Pressure Wire Guided Cardiac Resynchronisation Therapy
Condition: Heart Failure
Interventions: Procedure: Standard CRT Implant;   Procedure: Pressure-wire guided CRT implant
Outcome Measures: Change in the proportion of CRT responders at 6 months;   Change in clinical composite score at 6 months;   Change in echo derived endsystolic volume (ESV) at six months;   Change in echo derived enddiastolic colume (EDV) at six months;   Change in echo derived left ventricular ejection fraction (LVEF) at 6 months;   Six month assessment of change in symptoms (Minnesota Living with Heart Failure Questionnaire);   Six month change in 6 minute walk distance;   Six month change in VO2 max (CPET);   Six month change in ntProBNP;   Six month difference in hospital readmission (days);   Six month difference in mortality;   Difference in rates of successful LV lead implantation;   Difference in procedure duration;   Difference in radiation dose;   Difference in contrast dose;   Procedural complications
13 Recruiting Cryoablation in Patients With Atrial Flutter
Condition: Atrial Flutter
Interventions: Procedure: Cryoballoon ablation;   Procedure: Implantation of loop recorder;   Procedure: Radiofrequency ablation
Outcome Measures: Percentage of AF burden;   All-cause death;   thromboembolic events;   hospitalizations;   procedural complications;   drug adverse effects;   number of crossovers
14 Recruiting Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-High Risk Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Recurrent Neuroblastoma;   Regional Neuroblastoma
Interventions: Other: clinical observation;   Drug: carboplatin;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: isotretinoin;   Drug: topotecan hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: OS (Strata 1-4);   EFS (Stratum 5);   Time to intervention or tumor progression;   Type of intervention required;   Site of progression;   Pharmacokinetic (PK) profile of carboplatin and etoposide in patients with stage Ms disease, including peak concentration, area under the curve, clearance, volume of distribution, half-life, and mean residence time;   Genomic profile of tumors;   Histology of tumor specimens;   Salvage rate (OS) of patients with tumor relapse or disease progression;   Procedural complication rate;   Rate of reduction in IDRF in L2 tumors;   Bone abnormalities on bilateral tibial radiographs;   PK and pharmacogenomic parameters of isotretinoin
15 Not yet recruiting Left Ventricular Pacing to Prevent Iatrogenic TR Pilot Study
Conditions: Tricuspid Valve Insufficiency;   Sick Sinus Syndrome
Interventions: Device: LV pacing;   Device: RV pacing
Outcome Measures: Development of moderate or worse TR post implantation;   Biventricular ventricular function and dyssynchrony;   Major cardiovascular events;   All cause mortality;   Biomarkers of heart failure;   Lead performance parameters;   Procedural Complications and device related complications
16 Recruiting Comparison of Stent and Prothesis Bypass in Superficial Femoral Artery
Conditions: Arterial Occlusive Diseases;   Vascular Diseases
Interventions: Device: stent;   Device: femoral-popliteal bypass with artificial blood vessel
Outcome Measures: Occlusion of the stent or artificial blood vessel bypass;   Mortality;   Rate of limb salvage;   Procedural Complications, defined as any adverse event;   Quality of Life assessment;   Rate of amputation;   Increase in Ankle Brachial Index;   Restenosis measured by Duplex Ultrasound or CTA
17 Not yet recruiting Revascularization in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) With Multivessel and/or Unprotected Left Main Coronary Disease
Conditions: Multi Vessel Coronary Artery Disease;   Acute Coronary Syndrome
Interventions: Procedure: PCI;   Procedure: CABG
Outcome Measures: All cause death;   Composite of MACCE;   Procedural and post procedural complication;   Overall costs of treatment strategies.;   Occurence of stent thrombosis or graft occlusion;   Hemorrhagic complications.;   Frequency and impact of complete revascularization
18 Recruiting Stenting in the Treatment of Aneurysm Trial
Condition: Intracranial Aneurysm
Interventions: Device: endovascular coiling with any type of currently approved coil (first or second generation);   Device: endovascular stenting with or without coiling. The stent may be any of the currently approved stents for intracranial aneurysms.
Outcome Measures: Recurrence rate of target aneurysm;   Rate of Procedural Complications defined as number of subjects with reported peri-procedural Adverse Events;   Rate of mortality and morbidity defined as the number of subjects with a disabling neurological events as measured by a modified Rankin Score greater than 2 during the follow-up period;   Overall morbidity and mortality defined as a change in modified Rankin Score relative to baseline;   Incidence of in-stent stenosis defined as the number of subjects with a reduction in the luminal diameter of greater than 50%
19 Unknown  Impact of Left Atrial Appendage Exclusion on Short-Term Clinical Outcomes and Long-Term Stroke Incidence
Conditions: Atrial Fibrillation;   Thromboembolism;   Cerebrovascular Accident
Intervention: Procedure: Left Atrial Appendage Ligation
Outcome Measures: Incidence of Stroke;   Short- and Long-term biochemical parameters;   Short-term clinical outcomes (Procedural Complications, hospital length of stay, etc)
20 Recruiting MASCOT - Post Marketing Registry
Conditions: Coronary Artery Disease;   Atherosclerosis
Intervention: Device: OrbusNeich COMBO stent
Outcome Measures: Adjudicated device-oriented composite target lesion failure (TLF);   Adjudicated TLF;   Each of the components of TLF (Cardiac death, Non-fatal MI not clearly attributable to a non-target vessel, Target lesion revascularization (TLR));   Adjudicated patient-oriented composite Major Adverse Cardiac Events (MACE) as a composite of all Death, any MI and ischemia-driven revascularization (TLR/TVR/non-TVR);   Each of the components of MACE (All death, Any myocardial infarction, Ischemia-driven revascularization);   Adjudicated stent thrombosis per the Academic Research Consortium (ARC) definition;   Adjudicated bleeding per the Bleeding Academic Research Consortium (BARC) definition;   Adjudicated stroke;   Device success: Percentage of patients with a successful delivery and deployment of the Combo Stent to the target lesion and a final diameter stenosis after stenting ≤20% by visual assessment in the presence of grade 3 TIMI flow, by visual estimation;   Procedure success: Successful stent placement and no peri-Procedural Complications.

These studies may lead to new treatments and are adding insight into Loin etiology and treatment.

A major focus of Loin research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Loin